Literature DB >> 1546847

beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis.

Y Zhang1, V A Steingrube, R J Wallace.   

Abstract

Ten clinical isolates and the type strain (H37Rv) of Mycobacterium tuberculosis were shown to produce an intracellular beta-lactamase. Crude enzyme preparations were extracted from acetone cell powders by grinding with zirconium beads in 0.133 M glycine with 1.0% Triton X-100. The enzymes had identical patterns on isoelectric focusing, with two major bands at isoelectric points of 4.9 and 5.1. The beta-lactamase was highly susceptible to the new beta-lactamase inhibitor BRL 42715, with an I50 of 0.0001 microgram/ml. The enzyme was also susceptible to clavulanic acid with an I50 (0.05 microgram/ml), which was similar to the value for the common bacterial beta-lactamase TEM-1 (0.01 microgram/ml). The latter result is consistent with previous MIC studies with M. tuberculosis, which have shown synergy between clavulanic acid and amoxicillin. BRL 42715 and clavulanic acid were more active than sulbactam, tazobactam, and cloxacillin. These studies support the potential value of penicillin/clavulanic acid and penicillin/BRL 42715 combinations in the treatment of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546847     DOI: 10.1164/ajrccm/145.3.657

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

1.  Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

Authors:  Ying Kong; Hequan Yao; Hongjun Ren; Selvakumar Subbian; Suat L G Cirillo; James C Sacchettini; Jianghong Rao; Jeffrey D Cirillo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

2.  Altered permeability and beta-lactam resistance in a mutant of Mycobacterium smegmatis.

Authors:  S Mukhopadhyay; P Chakrabarti
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  C4-alkylthiols with activity against Moraxella catarrhalis and Mycobacterium tuberculosis.

Authors:  Maya B Kostova; Carey J Myers; Tim N Beck; Balbina J Plotkin; Jacalyn M Green; Helena I M Boshoff; Clifton E Barry; Jeffrey R Deschamps; Monika I Konaklieva
Journal:  Bioorg Med Chem       Date:  2011-10-01       Impact factor: 3.641

4.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 7.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

8.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  C Segura; M Salvadó; I Collado; J Chaves; A Coira
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds.

Authors:  M Galleni; N Franceschini; B Quinting; L Fattorini; G Orefici; A Oratore; J M Frère; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.